Deciphera Pharmaceuticals Future Growth
Future criteria checks 2/6
Deciphera Pharmaceuticals is forecast to grow earnings and revenue by 45% and 21.8% per annum respectively. EPS is expected to grow by 46.9% per annum. Return on equity is forecast to be -55% in 3 years.
Key information
45.0%
Earnings growth rate
46.9%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 21.8% |
| Future return on equity | -55.0% |
| Analyst coverage | Good |
| Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 375 | -71 | -49 | -103 | 8 |
| 12/31/2025 | 264 | -156 | -145 | -141 | 9 |
| 12/31/2024 | 202 | -196 | -176 | -147 | 9 |
| 12/31/2023 | 163 | -195 | -147 | -147 | N/A |
| 9/30/2023 | 151 | -194 | -154 | -153 | N/A |
| 6/30/2023 | 144 | -187 | -145 | -144 | N/A |
| 3/31/2023 | 138 | -182 | -152 | -151 | N/A |
| 12/31/2022 | 134 | -179 | -154 | -153 | N/A |
| 9/30/2022 | 122 | -221 | -185 | -185 | N/A |
| 6/30/2022 | 109 | -258 | -223 | -218 | N/A |
| 3/31/2022 | 100 | -286 | -230 | -224 | N/A |
| 12/31/2021 | 96 | -300 | -247 | -241 | N/A |
| 9/30/2021 | 91 | -274 | -230 | -223 | N/A |
| 6/30/2021 | 84 | -258 | -221 | -218 | N/A |
| 3/31/2021 | 67 | -255 | -232 | -227 | N/A |
| 12/31/2020 | 42 | -266 | -245 | -240 | N/A |
| 9/30/2020 | 23 | -271 | -253 | -246 | N/A |
| 6/30/2020 | 7 | -263 | -229 | -220 | N/A |
| 3/31/2020 | 25 | -218 | -202 | -197 | N/A |
| 12/31/2019 | 25 | -192 | -154 | -149 | N/A |
| 9/30/2019 | 25 | -157 | -124 | -120 | N/A |
| 6/30/2019 | 25 | -126 | -123 | -122 | N/A |
| 3/31/2019 | N/A | -126 | -104 | -103 | N/A |
| 12/31/2018 | N/A | -100 | -88 | -87 | N/A |
| 9/30/2018 | N/A | -87 | -74 | -73 | N/A |
| 6/30/2018 | N/A | -75 | -58 | -57 | N/A |
| 3/31/2018 | N/A | -64 | -47 | -46 | N/A |
| 12/31/2017 | N/A | -50 | -37 | -37 | N/A |
| 9/30/2017 | N/A | -39 | N/A | -31 | N/A |
| 6/30/2017 | N/A | -33 | N/A | -28 | N/A |
| 3/31/2017 | N/A | -28 | N/A | -25 | N/A |
| 12/31/2016 | N/A | -26 | N/A | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DCPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DCPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DCPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DCPH's revenue (21.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: DCPH's revenue (21.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DCPH is forecast to be unprofitable in 3 years.